Eli Lilly and Company $LLY Stock Position Increased by Calamos Advisors LLC

Calamos Advisors LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 2.2% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 289,232 shares of the company's stock after purchasing an additional 6,231 shares during the period. Eli Lilly and Company accounts for approximately 1.0% of Calamos Advisors LLC's holdings, making the stock its 11th biggest position. Calamos Advisors LLC's holdings in Eli Lilly and Company were worth $334,665,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Financial Council LLC increased its position in Eli Lilly and Company by 0.6% during the third quarter. Financial Council LLC now owns 1,255 shares of the company's stock valued at $1,452,000 after acquiring an additional 8 shares during the last quarter. Burke & Herbert Bank & Trust Co. lifted its holdings in shares of Eli Lilly and Company by 0.5% in the 3rd quarter. Burke & Herbert Bank & Trust Co. now owns 5,255 shares of the company's stock valued at $6,080,000 after buying an additional 24 shares during the period. Alta Advisers Ltd boosted its holdings in Eli Lilly and Company by 85.0% during the third quarter. Alta Advisers Ltd now owns 5,697 shares of the company's stock worth $6,592,000 after buying an additional 2,618 shares in the last quarter. Birchwood Financial Partners Inc. boosted its position in shares of Eli Lilly and Company by 10.9% during the third quarter. Birchwood Financial Partners Inc. now owns 203 shares of the company's stock worth $235,000 after buying an additional 20 shares during the period. Finally, Glaxis Capital Management LLC increased its holdings in Eli Lilly and Company by 20.9% in the third quarter. Glaxis Capital Management LLC now owns 5,660 shares of the company's stock valued at $6,549,000 after buying an additional 980 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly and Hims & Hers agreed to offer FDA-approved Zepbound and Foundayo through Hims & Hers’ telehealth platform. Eligible patients with a prescription can access Lilly’s self-pay prices—reportedly starting at $149—without leaving the platform. The deal could widen patient access and Lilly’s reach in the competitive obesity-treatment market. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
• Positive Sentiment: New Phase 3 results for investigational retatrutide showed substantial reductions in weight and knee pain among adults with obesity and knee osteoarthritis. Lilly also reported positive Phase 3b results for combining Taltz and Zepbound in people with psoriatic arthritis and obesity, supporting the potential of its medicines in additional patient groups. Lilly to showcase new retatrutide, Taltz and Zepbound data
• Negative Sentiment: Price competition across the GLP-1 market remains a risk to Lilly’s growth and drug margins, as branded treatments compete with lower-priced options and providers seek self-pay patients. Eli Lilly’s GLP-1 franchise faces growing price competition

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded up $7.42 during trading hours on Friday, hitting $1,372.15. 3,802,992 shares of the company traded hands, compared to its average volume of 2,624,130. The firm's 50-day simple moving average is $1,215.24 and its two-hundred day simple moving average is $1,101.16. The firm has a market cap of $1.29 trillion, a P/E ratio of 44.54, a P/E/G ratio of 1.77 and a beta of 0.40. Eli Lilly and Company has a 1-year low of $850.51 and a 1-year high of $1,453.00. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. During the same period last year, the company posted $7.02 EPS. The company's revenue was up 38.6% compared to the same quarter last year. As a group, analysts forecast that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company's payout ratio is 22.46%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Berenberg Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating and set a $1,400.00 price target for the company in a research report on Tuesday, September 15th. Royal Bank Of Canada raised their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an "outperform" rating in a research report on Friday, October 30th. Scotiabank increased their price target on shares of Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a "sector outperform" rating in a research report on Friday, October 30th. Citigroup boosted their price target on Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a "buy" rating in a report on Friday, October 30th. Finally, Argus upped their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a "buy" rating in a research note on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and an average target price of $1,404.14.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald Zakrowski sold 2,000 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares of the company's stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $17,020,770 in the last three months. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.